Back
Next-generation "trans-amplifying" mRNA vaccines
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: CEPI
Relevant to AI safety researchers interested in biosecurity and dual-use technology governance; ta-mRNA platforms exemplify how powerful emerging biotechnologies require careful oversight due to their potential for both beneficial pandemic response and misuse.
Metadata
Importance: 35/100organizational reportnews
Summary
CEPI (Coalition for Epidemic Preparedness Innovations) announces research into trans-amplifying mRNA (ta-mRNA) vaccines, a next-generation platform that could produce stronger immune responses at lower doses than conventional mRNA vaccines. This technology could enable faster, cheaper, and more scalable vaccine production for pandemic preparedness. The initiative represents a significant step in developing platform technologies for rapid response to emerging biological threats.
Key Points
- •Trans-amplifying mRNA vaccines use a self-replicating RNA mechanism to amplify antigen production, potentially requiring far lower doses than standard mRNA vaccines.
- •CEPI is funding research to advance ta-mRNA platforms as part of its 100 Days Mission to develop vaccines against novel pathogens within 100 days of a pandemic threat.
- •The technology could reduce manufacturing costs and increase global vaccine access, addressing equity concerns in pandemic response.
- •Lower dose requirements could allow existing manufacturing capacity to produce more vaccine doses, improving surge capacity during outbreaks.
- •This research has dual-use implications: the same amplification technology that enables rapid vaccine development could theoretically be misused for harmful biological applications.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| Bioweapons Risk | Risk | 91.0 |
Cached Content Preview
HTTP 200Fetched Mar 20, 20269 KB
Securing the Future: CEPI 3.0 Investment Case
[Find out more](https://cepi.net/securing-the-future) Dismiss
[Facebook](https://www.facebook.com/sharer/sharer.php?u=https://cepi.net/new-research-investigate-next-generation-trans-amplifying-mrna-vaccines) [LinkedIn](https://www.linkedin.com/shareArticle?mini=true&url=https://cepi.net/new-research-investigate-next-generation-trans-amplifying-mrna-vaccines) [X](https://twitter.com/intent/tweet?url=https://cepi.net/new-research-investigate-next-generation-trans-amplifying-mrna-vaccines)
- **Promising technology to be tested in preclinical studies funded by CEPI**
- **The innovation could enable up to 100 times less antigen-encoded mRNA per vaccine dose and for parts of the vaccine to be made ahead of an outbreak**
- **Some lifesaving COVID-19 vaccines use mRNA, and the innovation could be key to more rapidly responding to future threats**
**07 March 2024, OSLO, Norway and BOSTON, MA –** Scientists in the US are set to test a new vaccine approach that could overcome some of the challenges associated with the latest mRNA vaccine designs and more rapidly create pandemic-busting vaccines in as little as 100 days.
With up to US $1 million in funding from CEPI, researchers at Amplitude Therapeutics will perform preclinical studies that assess whether their trans-amplifying mRNA vaccine approach could provide a simplified alternative to the self-amplifying mRNA vaccine technique being used today.
Alongside conventional\* mRNA vaccines—the technology behind multiple safe and effective COVID-19 vaccines that have helped to save millions of lives—self-amplifying mRNA designs have become more prominent in recent years, with the first-ever licensure of a self-amplifying mRNA COVID-19 vaccine in Japan in [November 2023](https://newsroom.csl.com/2023-11-28-Japans-Ministry-of-Health,-Labour-and-Welfare-Approves-CSL-and-Arcturus-Therapeutics-ARCT-154,-the-first-Self-Amplifying-mRNA-vaccine-approved-for-COVID-in-adults).
Rather than the traditional vaccine approach of injecting an antigen (a substance that induces an immune response) directly into the recipient, mRNA platforms use the body’s own cell machinery to make the antigen. Self-amplifying mRNA vaccines are even more specialised as they contain genetic instructions that not only encode for the antigen but also replicase, an enzyme that serves as a built-in photocopier teaching the body how to make more mRNA.
While this self-copying design offers important advantages over conventional mRNA vaccines, such as the potential to reduce the dose of mRNA needed while maintaining the effectiveness of the vaccine, there are limitations. For example, the additional genetic instructions required for the replicase make the vaccine sequence at least three times longer than standard mRNA vaccine sequences which can lead to difficulties during manufa
... (truncated, 9 KB total)Resource ID:
7f893b5e738ec56f | Stable ID: YTY0NmVlMG